184 related articles for article (PubMed ID: 25735361)
1. Analysis of FHIT gene methylation in egyptian breast cancer women: association with clinicopathological features.
Zaki SM; Abdel-Azeez HA; El Nagar MR; Metwally KA; S Ahmed MM
Asian Pac J Cancer Prev; 2015; 16(3):1235-9. PubMed ID: 25735361
[TBL] [Abstract][Full Text] [Related]
2. The clinicopathological significance and drug target potential of FHIT in breast cancer, a meta-analysis and literature review.
Su Y; Wang X; Li J; Xu J; Xu L
Drug Des Devel Ther; 2015; 9():5439-45. PubMed ID: 26491255
[TBL] [Abstract][Full Text] [Related]
3. Promoter methylation status of the FHIT gene and Fhit expression: association with HER2/neu status in breast cancer patients.
Jeong YJ; Jeong HY; Lee SM; Bong JG; Park SH; Oh HK
Oncol Rep; 2013 Nov; 30(5):2270-8. PubMed ID: 23969757
[TBL] [Abstract][Full Text] [Related]
4. Assessment of the prognostic value of methylation status and expression levels of FHIT, GSTP1 and p16 in non-small cell lung cancer in Egyptian patients.
Haroun RA; Zakhary NI; Mohamed MR; Abdelrahman AM; Kandil EI; Shalaby KA
Asian Pac J Cancer Prev; 2014; 15(10):4281-7. PubMed ID: 24935385
[TBL] [Abstract][Full Text] [Related]
5. Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer.
Iliopoulos D; Guler G; Han SY; Johnston D; Druck T; McCorkell KA; Palazzo J; McCue PA; Baffa R; Huebner K
Oncogene; 2005 Feb; 24(9):1625-33. PubMed ID: 15674328
[TBL] [Abstract][Full Text] [Related]
6. Mutational and promoter hypermethylation status of FHIT gene in breast cancer patients of Kashmir.
Syeed N; Husain SA; Sameer AS; Chowdhri NA; Siddiqi MA
Mutat Res; 2011 Feb; 707(1-2):1-8. PubMed ID: 21095196
[TBL] [Abstract][Full Text] [Related]
7. FHIT gene and flanking region on chromosome 3p are subjected to extensive allelic loss in Egyptian breast cancer patients.
Ismail HM; Medhat AM; Karim AM; Zakhary NI
Mol Carcinog; 2011 Aug; 50(8):625-34. PubMed ID: 21557333
[TBL] [Abstract][Full Text] [Related]
8. Two-hit inactivation of FHIT by loss of heterozygosity and hypermethylation in breast cancer.
Yang Q; Nakamura M; Nakamura Y; Yoshimura G; Suzuma T; Umemura T; Shimizu Y; Mori I; Sakurai T; Kakudo K
Clin Cancer Res; 2002 Sep; 8(9):2890-3. PubMed ID: 12231533
[TBL] [Abstract][Full Text] [Related]
9. Association of the hypermethylation status of PTEN tumor suppressor gene with the risk of breast cancer among Kurdish population from Western Iran.
Yari K; Payandeh M; Rahimi Z
Tumour Biol; 2016 Jun; 37(6):8145-52. PubMed ID: 26715274
[TBL] [Abstract][Full Text] [Related]
10. Association of the promoter methylation and protein expression of Fragile Histidine Triad (FHIT) gene with the progression of differentiated thyroid carcinoma.
Yin DT; Wang L; Sun J; Yin F; Yan Q; Shen R; He G; Gao JX
Int J Clin Exp Pathol; 2010 May; 3(5):482-91. PubMed ID: 20606729
[TBL] [Abstract][Full Text] [Related]
11. [Promoter methylation profile in breast cancer].
Roa JC; Anabalón L; Tapia O; Martínez J; Araya JC; Villaseca M; Guzmán P; Roa I
Rev Med Chil; 2004 Sep; 132(9):1069-77. PubMed ID: 15543763
[TBL] [Abstract][Full Text] [Related]
12. Analysis of the fragile histidine triad (FHIT) gene in lobular breast cancer.
Huiping C; Jonasson JG; Agnarsson BA; Sigbjornsdottir BI; Huebner K; Ingvarsson S
Eur J Cancer; 2000 Aug; 36(12):1552-7. PubMed ID: 10930803
[TBL] [Abstract][Full Text] [Related]
13. [Alteration of methylation status of fragile histidine triad gene promoter in patients with myelodysplastic syndrome].
Yao DM; Qian J; Xu WR; Lin J; Jiang YW; Fei X; Han LX; Wang Y; Cen JN; Chen ZX
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Feb; 25(1):36-9. PubMed ID: 18247301
[TBL] [Abstract][Full Text] [Related]
14. FHIT expression and hypermethylation in esophageal squamous cell carcinoma.
Noguchi T; Takeno S; Kimura Y; Uchida Y; Daa T; Yokoyama S; Gabbert HE; Mueller W
Int J Mol Med; 2003 Apr; 11(4):441-7. PubMed ID: 12632095
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic alterations by methylation of RASSF1A and DAPK1 promoter sequences in mammary carcinoma detected in extracellular tumor DNA.
Ahmed IA; Pusch CM; Hamed T; Rashad H; Idris A; El-Fadle AA; Blin N
Cancer Genet Cytogenet; 2010 Jun; 199(2):96-100. PubMed ID: 20471512
[TBL] [Abstract][Full Text] [Related]
16. Aberrant methylation of Fragile Histidine Triad gene is associated with poor prognosis in early stage esophageal squamous cell carcinoma.
Lee EJ; Lee BB; Kim JW; Shim YM; Hoseok I; Han J; Cho EY; Park J; Kim DH
Eur J Cancer; 2006 May; 42(7):972-80. PubMed ID: 16564166
[TBL] [Abstract][Full Text] [Related]
17. Loss of fragile histidine triad gene expression in advanced lung cancer is consequent to allelic loss at 3p14 locus and promoter methylation.
Wali A; Srinivasan R; Shabnam MS; Majumdar S; Joshi K; Behera D
Mol Cancer Res; 2006 Feb; 4(2):93-9. PubMed ID: 16513840
[TBL] [Abstract][Full Text] [Related]
18. Quantitative detection of methylation of FHIT and BRCA1 promoters in the serum of ductal breast cancer patients.
Liu L; Sun L; Li C; Li X; Zhang Y; Yu Y; Xia W
Biomed Mater Eng; 2015; 26 Suppl 1():S2217-22. PubMed ID: 26406001
[TBL] [Abstract][Full Text] [Related]
19. Reduced acetylated histone H4 is associated with promoter methylation of the fragile histidine triad gene in resected esophageal squamous cell carcinoma.
Tzao C; Sun GH; Tung HJ; Hsu HS; Hsu WH; Wang YC; Cheng YL; Lee SC
Ann Thorac Surg; 2006 Aug; 82(2):396-401; discussion 401. PubMed ID: 16863736
[TBL] [Abstract][Full Text] [Related]
20. Aberrant methylation of the FHIT gene in chronic smokers with early stage squamous cell carcinoma of the lung.
Kim JS; Kim H; Shim YM; Han J; Park J; Kim DH
Carcinogenesis; 2004 Nov; 25(11):2165-71. PubMed ID: 15231689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]